Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MCF7 Etoposide
0.0033333
Topo II
Chemotherapy
 0.9807 -0.00208
MCF7 Etoposide
0.01
Topo II
Chemotherapy
 0.9547 -0.00321
MCF7 Etoposide
0.031667
Topo II
Chemotherapy
 0.8458 -0.00176
MCF7 Etoposide
0.1
Topo II
Chemotherapy
 0.6254 0.01057
MCF7 Etoposide
0.31623
Topo II
Chemotherapy
 0.2288 0.07777
MCF7 Etoposide
1.0
Topo II
Chemotherapy
 -0.0382 0.04534
MCF7 Etoposide
3.1623
Topo II
Chemotherapy
 -0.0441 0.04288
MCF7 Etoposide
10.0
Topo II
Chemotherapy
 -0.0274 0.06621
MCF7 Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 0.9751 0.00258
MCF7 Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 0.9725 0.00705
MCF7 Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 0.9260 0.00884
MCF7 Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 0.7662 0.02021
MCF7 Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.3935 0.04361
MCF7 Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 0.1795 0.06106
MCF7 Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 0.1326 0.06127
MCF7 Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 0.2004 0.05568
MCF7 Dasatinib
10.0
BCR/ABL
MAPK/nRTK
 0.1574 0.09974
MCF7 Trametinib
0.0001
MEK
MAPK/nRTK
 1.0030 -0.00089
MCF7 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9882 0.00197
MCF7 Trametinib
0.001
MEK
MAPK/nRTK
 0.8862 0.00743
MCF7 Trametinib
0.0031623
MEK
MAPK/nRTK
 0.7733 0.00910
MCF7 Trametinib
0.01
MEK
MAPK/nRTK
 0.6358 0.01384
MCF7 Trametinib
0.031623
MEK
MAPK/nRTK
 0.6023 0.01854
MCF7 Trametinib
0.1
MEK
MAPK/nRTK
 0.5517 0.02144
MCF7 Trametinib
0.31623
MEK
MAPK/nRTK
 0.5581 0.01735